Archive

Primary care physicians dealing with chronic pain

New research from Brigham and Women’s Hospital finds benefits in careful monitoring of chronic pain patients and need for pain management within primary care.

Benzodiazepine use not linked to dementia

by Bruce Sylvester: Benzodiazepine therapy in older adults is not associated with an increase in dementia risk, researchers reported on Feb. 2, 2016 in The BMJ today.

Clot-buster lowers death risk in deadliest stroke

by Bruce Sylvester: Tissue plasminogen activator (tPA) treatment with the clot-busting drug alteplase appears to be an effective way to decrease mortality in intraventricular hemorrhage, a catastrophic type… read more.

World Health Matters: The Netherlands: HIV epidemic persists in the Netherlands

by Gary Finnegan: HIV is easier than ever to prevent, detect and treat. Yet while life expectancy for people with the virus have improved over the past decade,… read more.

ASH 2015: Building good combinations. Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) discusses the benefits of building good combinations early on in therapy and the impact that newly available triplet oral therapy will have on patients with myeloma

ASH 2015: Good news for patients from ASH! Erik Low (Chief Executive Myeloma UK), Professor Antonio Palumbo (University of Torino, Italy), Professor Paul Richardson (Harvard Medical School, Boston, USA) and Dr Shaji Kumar (Mayo Clinic, Rochester, USA) discuss the things they will take home to their myeloma patients folloing ASH 2015

ASH 2015: Video Interview by Esther Drain. CDF changes affecting myeloma patients. Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Erik Low (Chief Executive Myeloma UK) discuss recent changes in the CDF and how they affect myeloma patients.

ASH 2015: We ask Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) what the role of PET/CT is as a measure of MRD post ASCT and ask Professor Antonio Palumbo (University of Torino, Italy) and Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) whether MRD measurement is ready for clinical use

Role of minimal residual disease in treatment tailoring divides experts by Thomas R. Collins Minimal residual disease (MRD) is a guide for tailoring multiple myeloma whose time has… read more.

ASH 2015: Video Interview by Esther Drain. Myeloma XI initial response data at ASH. Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) discusses the initial response data from Myeloma XI and whether early intensive therapy is the way forward in managing myeloma, with comment also from Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA).

ASH 2015: Ernest Beutler Lecture Prize: Award-winners trace history of proteasome and its starring role in MM treatment: Interview with Alfred Goldberg, PhD, Professor of Cell Biology at Harvard Medical School, and Paul Richardson, MD, Professor of Medicine at the Dana-Farber Cancer Center

by Thomas R. Collins: Standing at the center of a decade and a half of stunning advancements in the treatment of multiple myeloma is the ubiquitin proteasome pathway… read more.

ASH 2015: Myeloma X (intensive) trial update: Professor Gordon Cook (Leeds Teaching Hospitals, UK) gives an update on Myeloma X and discusses the role of transplant in myeloma in the age of novel agents

ASH 2015: Professor Antonio Palumbo (University of Torino, Italy), Dr Shaji Kumar (Mayo Clinic, Rochester, USA), Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Professor Gordon Cook (Leeds Teaching Hospitals, UK) give their highlights.